A framework for assessing the risk of resistance for anti-malarials in development

Xavier C Ding*, David Ubben and Timothy NC Wells

Abstract

Resistance is a constant challenge for anti-infective drug development. Since they kill sensitive organisms, anti-infective agents are bound to exert an evolutionary pressure toward the emergence and spread of resistance mechanisms, if such resistance can arise by stochastic mutation events. New classes of medicines under development must be designed or selected to stay ahead in this vicious circle of resistance control. This involves both circumventing existing resistance mechanisms and selecting molecules which are resilient against the development and spread of resistance. Cell-based screening methods have led to a renaissance of new classes of anti-malarial medicines, offering us the potential to select and modify molecules based on their resistance potential. To that end, a standardized in vitro methodology to assess quantitatively these characteristics in Plasmodium falciparum during the early phases of the drug development process has been developed and is presented here. It allows the identification of anti-malarial compounds with overt resistance risks and the prioritization of the most robust ones. The integration of this strategy in later stages of development, registration, and deployment is also discussed.

Keywords: Resistance, P. falciparum, Drug development, Risk assessment

Background

Resistance is a phenomenon common to all anti-infective agents that can be defined as a genetically encoded reduction in efficacy of a drug. Anti-malarial medicines are amongst the most commonly used drugs worldwide, and historically the supervision of their administration has been relatively unsupervised. This combination of factors has led to the successive demise of first line treatments such as chloroquine, proguanil, pyrimethamine, sulphadoxine-pyrimethamine and mefloquine, which are unable to produce a 90% clinical response in many areas where they have been deployed intensively [1,2]. Some medicines are clearly more prone to resistance selection than others: resistant strains to chloroquine took decades to emerge, but those to the electron transport inhibitor atovaquone were identified almost in parallel with its first clinical use [3]. This difference has a clear molecular basis: chloroquine resistance requires several mutations in the transporter pfert (chloroquine resistance transporter), whilst atovaquone resistance requires a single point mutation in the mitochondrially encoded cytochrome bc1 pf cyt b (cytochrome b) [4]. Altogether, the nature of antimalarial compounds, of their targets, and of the interactions between them ultimately determines the genetic ability of Plasmodium parasites to acquire resistance mechanisms. Whether these mechanisms will emerge and spread in the wild further depends on several factors operating at the host and population levels (Table 1).

Fortunately, development of resistance to artemisinin, on which are based current first-line therapies for uncomplicated and severe P. falciparum malaria, has been relatively slow. This is partly due to recommendations from the World Health Organization (WHO) that only fixed-dose combinations of artemisinin derivatives with other anti-malarials should be used. It is also because of the relative difficulty of generating artemisinin resistance, which has been reassuringly problematic, even in the laboratory [5]. The first signs of a reduction of the anti-parasitic activity of artemisinins are emerging, with a decrease in parasite clearance time being seen in Cambodia and Thailand, and the first hints of a possible

* Correspondence: dingx@mmv.org
1 Medicines for Malaria Venture, 20 rte de Pré Bois, Geneva CH 1215, Switzerland
Full list of author information is available at the end of the article

© 2012 Ding et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
molecular mechanism have been suggested [6-8]. Even if the spread of resistance can be controlled, there will be a need for new classes of anti-malarial drugs. This is a race against time, given that the time taken to develop new medicines often exceeds a decade. Developing new medicines that will withstand resistance is a combination of reducing the possibility that resistant parasites will arise and preventing their transmission. First, finding new molecular classes with a low probability that resistance would arise should be a consequence of more holistic cellular based screening, which has the advantage of potentially selecting for polypharmacology; in other words molecules that hit more than one target. Fitness cost is a key factor in this equation as well: if it is not possible to produce a resistant phenotype with a low fitness cost, then these strains are likely to be replaced by sensitive strains when the drug pressure is relaxed. Second, understanding the role of new inhibitors on transmission is also critical at an early stage, since resistant parasites which are inefficiently transmitted are a far lower threat to global public health concern. Anti-folate resistance had a marked differential effect on transmission which may have accelerated its spread [9]: clearly a molecular class with the opposite trend would be preferable. Third, the spread of resistance can be reduced by combining multiple agents with distinct modes of action; since any organism resistant to one component of the combination should be eliminated by the other. This raises the barrier for resistance, since the parasite would have to acquire both resistances simultaneously, which is far less likely, assuming the mutation events are stochastic [10]. The combination of artesunate-lumefantrine has been protected against the emergence of lumefantrine resistance despite being used to treat over 500 million patients, partly because lumefantrine has never been used as a monotherapy. Fixed dose combinations prevent sub-optimal monotherapy treatment, and will restrict the spread of resistance [10,11], provided the optimal dose ratio can be deployed. Multiple first-line therapies would also help, but the key is to have medicines which are as different as possible and current strategies would only allow use of artemisinin combination therapies [12,13]. Putting together these three factors in models to simulate drug resistance emergence in the wild is an important task, but is still at an early stage [14-16].

The lifespan of the next generation of anti-malarials in the face of resistance is a critical question in the debate over malaria elimination and eradication. If through judicious selection of the right molecules and good practice, the time interval from introduction to clinically significant resistance for the next generation of therapy can be put at the level of artemisinin, or even better, it is possible that the disease will be eliminated before clinical resistance occurs. This increases the need to have an early assessment of the risk of developing resistance associated with each compound and each combination. This would not be the single decision criterion, but would be part of the overall framework of deciding which compounds to prioritize. The Medicines for Malaria Venture (MMV) is a product development partnership with the mission to discover, develop, and facilitate delivery of new, effective and affordable anti-malarial

| Table 1 Resistance associated factors |
|--------------------------------------|
| **Factor**                           | **Level of action** | **Variables**                                                                 |
| Drug mode-of-action                  | Parasite           | Target nature (cellular process, protein, other).                              |
|                                     |                    | Target gene localization (nuclear or mitochondrial genome).                    |
|                                     |                    | Drug subcellular localization (vacuole, organelle, cytoplasm).                 |
| Resistance mode-of-action            | Parasite           | Target mutation rate.                                                          |
|                                     |                    | Nature of mutations required for resistance (single nt, in/del, copy number).   |
|                                     |                    | Number of mutations required for resistance (causal and compensating).          |
| Fitness                              | Human host         | Growth rate of resistant parasite (within host competition)                     |
|                                     |                    | Effect of drug on gametocyto genesis and gametocyte viability.                  |
|                                     |                    | Effect of resistance mutations on gametocyto genesis and gametocyte viability.  |
| Drug pharmacokinetic                 | Human host         | Clinical parasite reduction ratio                                               |
|                                     |                    | Drug half-life                                                                  |
|                                     |                    | Drug dosage                                                                     |
| Drug deployment                      | Human population   | Drug pressure                                                                   |
|                                     |                    | Drug combination                                                                |
|                                     |                    | Parasite transmission intensity                                                 |
|                                     |                    | Human population immunity                                                       |

Ding et al. Malaria Journal 2012, 11:292
http://www.malariajournal.com/content/11/1/292
medicines. Part of the process of developing new medicines is to have a coherent view on the required properties of new medicines, a process often referred to as developing the ‘target product profile’ or TPP. Since one key aspect of this product profile has to be minimal susceptibility to resistance, it is important to have a standardized framework to quantitatively assess the risk of resistance associated with preclinical anti-malarial compounds. Such a framework, based on in vitro P. falciparum experiments, has been developed and is presented. The experimental strategy is discussed together with the benefits and limitations of such a standard approach and its implications for clinical development.

Resistance assessment strategy
The MMV assessment strategy has been designed to achieve three goals: (i) identify potential cross-resistance to other anti-malarial compounds and naturally occurring phenotypic differences, (ii) quantify the risk, or frequency, of de novo resistance selection in vitro and the associated fitness cost, (iii) characterize the molecular mode-of-action of resistance, including an understanding of its genetic basis. This work goes on in parallel with the optimization and selection of candidate molecules. Clearly not all work needs to be done on all molecules in the discovery pipeline, since the sad truth is that most chemical series do not result in a molecule which can be tested in humans. The first aspect should be analysed when a new chemical series is identified, since this is something that may be optimized by a medicinal chemistry approach. The second aspect is probably series dependent, and requires more intensive measurement, and should wait until a project is at the lead optimization stage. The final steps should be carried out in parallel to the clinical candidate selection, since they are relatively labour intensive. Two test cascades have been defined to achieve the first two goals systematically, the results of which can be exploited to the third one (Figure 1).

Goal I: cross-resistance
One of the hallmarks of genetically determined drug-resistance is a shift in the 50% inhibitory concentration (IC50) compared to sensitive strains. The first step is establishing that a new compound is fully active on known multi-drug resistant (MDR) P. falciparum strains by measuring its IC50, which is a more robust and reproducible measure than IC90 or IC99. Known anti-malarial resistance is principally determined by only a handful of genes (Figure 2). These include specific molecular targets, such as those for antifolates pfdhps (dihydropteroate synthase) and pfdhfr (dihydrofolate reductase) and electron transport inhibitors pf cyt b (cytochrome bc1). In addition there are transporters such as pfcr t (chloroquine) and pfmdr1 (multidrug resistance 1).

A collection of resistant strains has been selected to cover at least all the naturally occurring and genetically defined known resistance mechanisms (Table 2). In this context, we will define resistance as IC50 value 20-fold higher than that of the reference IC50 value from a pan-sensitive P. falciparum strain, typically NF54. This threshold gives room for intrinsic IC50 variations in the growth rate or other biological or experimental parameters not directly related to resistance mechanisms [17]. The strains selected cover the majority of known genetic variations. The chloroquine transporter pfcr t mutation K76T is associated with additional mutations (CVIET and SVMNT alleles which are found in the FCB and 7G8 strains). The V1/S strain has mutations in pfdhfr leading to four amino acid substitutions showing high levels of resistance to cycloguanil and pyrimethamine [18]. HB3 is resistant to pyrimethamine but not cycloguanil, while FCB shows the contrary pattern [18]. Dd2 and FCB show increased copy numbers of pfmdr1, and mutations at several codons. These changes influence sensitivity to multiple drugs, including mefloquine and artesiminin derivatives [5,19]. NF54 and 7G8 have a 20-fold shift in IC50 to sulphadoxine, as a result of mutations in pf dhps whilst Dd2 has a high level resistance, when tested in a low para-aminobenzoic acid (pABA) medium [20,21]. TM90C2B is resistant to atovaquone, due to a mutation in pf cytb [22]. Finally the set also includes the D6 strain, which shows, in some studies, a low level of natural resistance to mefloquine [23]. The K1 strain recapitulates most of the natural resistance mechanisms described above and therefore is a good first filter that can be performed early in the screening process. Clearly over the next few years it will be important to add new resistance mechanisms. For example, resistance to the new spiroindolone NITD609 (in Phase IIa) is linked to pfatp4 as a potential resistance mechanism [24], demonstrating that new classes of compounds can bring new resistance mechanisms.

Since these MDR strains were adapted to culture and cloned many years ago, and have been passaged since that time, they may not represent the wild-type field Plasmodium parasites. Moreover, only P. falciparum can be stably cultured in the laboratory. It is therefore essential to test compounds against contemporary field isolates of all the human-infecting species, including Plasmodium vivax, Plasmodium ovale and Plasmodium malariae. This gives good background information on variability, and allows confirmation that the compound is active on all species. The analysis of at least 10 P. falciparum and 10 P. vivax isolates appears a minimal requirement, if a 20-fold change in IC50 is used as a cut-off [42].
Figure 1 Resistance risk assessment workflow. The resistance risk assessment workflow encompasses three goals: cross-resistance determination (goal I), de novo resistance selection frequency determination (goal II), and resistance mode-of-action determination (goal III). These can be achieved through a straightforward set of quantitative experiments applied to compounds at the lead and preclinical developmental stages. A resistant IC_{50} corresponds to a 20-fold increase as compared to a fully sensitive strain (NF54 or HB3 in the case of sulphonamides). C is the theoretical cost of fitness associated with resistance (see main text). C<0 indicates that resistance provides a fitness advantage, which is a major risk factor. Ultimately, the overall risk level can be classified as low, elevated, or major and allows to prioritize the development of robust compounds and to establish risk mitigation strategies for the others.

Figure 2 Known genetic determinants of naturally occurring resistance mechanisms. Mutations (red dot) of the dihydrofolate reductase (PfDHFR) enzyme prevent its inhibition by the antifolate drugs pyrimethamine (PYR) and cycloguanil (CYC). Similarly, sulphadoxine (SDX) resistance is mediated by mutations of its target dihydropteroate synthetase (PfDHPS). Atovaquone (ATO) binds to the cytochrome bc_{1} complex (PfCYTB), mutations of which have been shown to induce high level of ATO resistance. Chloroquine (CHQ) is believed to prevent haeme detoxification within the digestive vacuole. Mutations of the CHQ resistance transporter (PfCRT) as well as of the multidrug resistance protein-1 (PfMDR1), including copy number variations, have been shown to compromise CHQ action by preventing its accumulation within the digestive vacuole. Mutations of these two transporters have also been implicated with mefloquine resistance, although definite marker has not been established for this drug.
Table 2  Panel of multidrug resistant strains including specific amino acid changes

| Strain | drug resistance | pfcrtb | pfmdr1c | pfdhfrd | pfdhpsde | pfctybe |
|--------|-----------------|--------|---------|---------|---------|--------|
|        | CHQ  | SUL  | PYR  | CYC  | MEF  | ATO  | copy | 16 | 51 | 59 | 108 | 164 | 436 | 437 | 581 | 613 | 268 |
| N54    | S     | S     | S     | S     | S     | S     | C     | V     | M     | N     | K     | Y     | S     | N     | D     | I     | A     | N     | C     | S     | I     | S     | G     | A     | A     | Y     | Imported | MRA-100 | [25] |
| D6     | S     | S     | S     | R     | S     | C     | V     | M     | N     | K     | N     | Y     | S     | N     | D     | I     | A     | N     | C     | S     | I     | A     | A     | A     | Cloned from Sierra Leone CDC | MRA-285 | [26] |
| HB3    | S     | S     | R     | S     | S     | S     | C     | V     | M     | N     | K     | N     | Y     | S     | D     | D     | I     | A     | N     | C     | N     | I     | S     | A     | A     | Cloned from Honduras CDC | MRA-155 | [27] |
| 7 G8   | R     | S     | R     | R     | S     | S     | S     | V     | M     | N     | T     | N     | F     | C     | D     | Y     | I     | A     | I     | C     | N     | I     | S     | G     | A     | A     | Cloned from IMTM 22 (Brazil) | MRA-152 | [28] |
| Dd2    | R     | R     | R     | R     | R     | R     | C     | V     | I     | E     | T     | Y     | Y     | S     | N     | D     | 4     | A     | I     | R     | N     | I     | F     | G     | A     | S     | Cloned from W2-Mef (Indochina III/CDC) | MRA-150 | [29] |
| V1/S   | R     | R     | R     | R     | R     | R     | C     | V     | I     | E     | T     | Y     | Y     | S     | N     | D     | A     | I     | R     | N     | L     | F     | G     | A     | T     | Cloned from V1 (Vietnam) | MRA-176 | [30] |
| K1     | R     | R     | R     | R     | R     | R     | C     | V     | I     | E     | T     | Y     | Y     | S     | N     | D     | 1     | A     | N     | R     | N     | I     | S     | G     | G     | A     | Thailand | MRA-159 | [31] |
| FCB    | R     | S     | R     | C     | V     | I     | E     | T     | Y     | Y     | S     | N     | D     | 2     | V     | N     | C     | T     | I     |     |
| TM90C2B| R     | R     | R     | R     | C     | V     | I     | E     | T     | N     | F     | S     | N     | D     | S     |     |

*a: sensitive, R: resistant, as reported in the literature.
*b Allelic information based on references [33-35].
*c Allelic information based on references [33,35-37].
*d Allelic information based on references [18,35,38].
*e Allelic information based on references [20,39-41].
Goal II: resistance selection frequency

Resistant parasites can be selected by applying drug pressure in vitro and in vivo [22]. These approaches have successfully identified genes, and sometimes codons involved in naturally occurring resistance [22]. The single nucleotide changes behind these mutations are estimated to occur at a rate of approximately $10^{-9}$ per nucleotide site per replication, similar to other eukaryotes [43-45]. Changes in sensitivity are also caused by gene copy number variations, which occur as often as $10^{-4}$ per nucleotide site per replication [45,46].

The simplest approach is in vitro selection of resistant parasites, which can be applied on a large number of compounds earlier in drug discovery. *P. falciparum* intraerythrocytic cultures, with starting inocula ranging from $10^5$ to $10^9$ parasites, are exposed to a concentration of the compound nearing IC$_{50}$ and monitored during 60 days for recrudescent parasites (Figure 3a). The minimal inoculum for resistance (MIR) can be determined and is an indirect measure of the likelihood of a resistant genotype to occur and to be selected in vitro. In addition, the IC$_{50}$ shift of the resistant mutants as compared to the parental sensitive strain is a measure of the resistance intensity [47-49]. Dd2 has an accelerated resistance to multiple drugs (ARMD) phenotype, possibly due to defective DNA repair mechanisms [47,50], and is therefore an ideal strain to investigate rare mutational events within the practical limits of in vitro culture volumes. Importantly, MIR from ARMD strains are assumed to be lower because of the general higher mutation rate of these parasites and not because they acquire alternative resistance mechanisms. Moreover, ex vivo results seem to be in good agreement with clinical experience. Atovaquone resistance is generated relatively easily in patients, and in laboratory experiments do not allow to control the level of drug pressure or the number of parasite subjected to it and are not ideal to profile and cross-compare a large number of early compounds.

A combination of MIR and IC$_{50}$ increase in Dd2 can be used to flag compounds at high risk of resistance (Figure 3b). An MIR equal to or below $10^5$ is a major risk, as it suggests that only a single nucleotide mutation is sufficient. A MIR of $10^7$ would also be high risk, if combined with a greater than 20-fold shift in the IC$_{50}$. Combinations of MIR and IC$_{50}$ shift data available in the literature are presented in the Figure 3b and Table 3. This limited data set shows strain dependence of MIRs, atovaquone showing an MIR of $10^7$ for in W2 and at $6 \times 10^8$ in K1 [4,47]. For example, the confirmation that cyclopropyl carboxamides had an MIR of less than $10^8$ in the standard 3D7 strain, and an IC$_{50}$ shift of 100-fold range, gives two clear signals that the series should be put on hold, unless other redeeming features can be identified [51].

Mutations that give a selective advantage against drugs often cause a reduction in fitness in its absence [53,54]. A key fitness parameter is the relative asexual growth rate [55], measured in vitro by monitoring cultures seeded with the derived resistant and the original (sensitive) parental strain at a given ratio. The evolution of the strain ratio can then be monitored by DNA sequencing or qPCR [56-58]. The proportional loss of fitness (C) can be calculated from the change in strain ratio $\Delta R_n$ after n generations, where that value is equal to $1/(1-C)^n$ [58]. If C ≥ 0 the sensitive strain will outgrow the resistant strain, however, if C<0 this would be major potential risk, suggesting that the strain may also out-compete the original wild type in humans. Of note, such a scenario has already been observed with *P. chabaudi* chloroquine and pyrimethamine resistant parasites displaying a fitness gain even in the absence of drug pressure [53]. A second key parameter of parasite fitness is its transmission potential, which depends not only on its growth rate but also on its ability to produce viable gametocytes. The effect of resistance can also be investigated on the sexual phase of the parasite cycle, using recently developed in vitro methods [59]. A resistant parasite unable to complete a sexual cycle is of no clinical relevance, as it cannot be transmitted.

In vivo resistance selection experiments allow a more physiological variation of the drug concentration and are more representative of the clinical situation [60]. For instance, the *pfcytb* Y268C mutation conferring atovaquone resistance in the wild could only be reproduced using a rodent in vivo model [61]. However, in vivo experiments do not allow to control the level of drug pressure or the number of parasite subjected to it and are not ideal to profile and cross-compare a large number of early compounds.

Goal III: understanding the molecular mechanism of resistance

One key to understanding the importance of a resistant phenotype is its molecular characterization. Mutations in genes encoding pumps and transporters are concerning, since they could imply parallel resistance generation to a wide variety of different molecules. Point mutations may enable a link with the molecular target to be established. The genetic changes causing resistance can be identified using tiling arrays, full genome sequencing or linkage analysis and candidate genes can be validated using allelic exchange experiments [62-65]. The full genome sequences of a large number of *P. falciparum* parasites from diverse locations have already been determined [66]. For those molecules like NITD609 for which molecular markers of resistance have already been identified, it will also be important to examine these sequences and determine whether the target gene is
highly polymorphic in these natural populations. This straightforward examination will give advance warning of any regions where resistant parasites might already be present, and easily selected by use of the drug. Additionally, in vitro experiments performed to characterize the compound speed of action and its activity at various stages of the parasite lifecycle can be repeated using resistant parasites in order to better understand

**Figure 3 In vitro resistance selection assessment.** (a) A standard in vitro protocol for resistance selection frequency measurement uses defined starting inocula of a P. falciparum strain pressured with a constant level of drug nearing the IC₉₀. Parasitemia falls below detection limits but eventual resistant parasites are able to recrudesce and to be cloned for subsequent determination of the IC₅₀ fold increase. The minimal inoculum for resistance (MIR) is a measure of the resistance selection frequency, while the IC₅₀ fold increase measures the level of resistance. (b) These two endpoints are used to classify anti-malarial compounds according to risk levels (see main text). It is advisable to run control experiments in parallel with compounds known to select resistance readily, such as atovaquone.

**Table 3 MIR and associated IC₅₀ fold increase reported in the literature**

| Compound       | Strain | Pressure     | MIR       | IC₅₀ fold increase | Mechanism                  | Ref. |
|----------------|--------|--------------|-----------|--------------------|----------------------------|------|
| Atovaquone     | W2     | 10xIC₉₀      | 1x10⁵     | 30x                | n/a                        | [47] |
| Atovaquone     | K1     | 6x/16xIC₅₀   | 6x10⁵     | 900x               | single point mutations in pfcytb | [4]  |
| Piperaquine    | Dd2    | 2xIC₉₀       | 8.5x10⁸   | 100x               | 63-kb fragment amplification | [49] |
| Chloroquine    | 106/1  | 3xIC₉₀       | 6x10⁸     | 100x               | single point mutations in pfcrt | [52] |
| GSK2645947     | 3D7    | 10xIC₉₀      | <1x10⁸    | 100x               | n/a                        | [51] |

* n/a: non available.
the resistance mode-of-action [59,67]. Recent advances in imaging also allow monitoring the intraerythrocytic life cycle of the parasites in vitro and in vivo and could similarly be used to compare resistant and sensitive parasites [68].

**Clinical and regulatory requirement**

The development of technologies for assessing resistance means that comprehensive resistance testing should take place at all phases of drug development, including post-marketing pharmacovigilance (Figure 4). Ideally, the preclinical studies will have produced resistant strains and identified resistance markers, which are especially useful in the post-marketing surveillance phase. Resistance selection could also be performed for both partners of potential therapeutically combination using single-resistant mutants to evaluate the frequency of double-resistance, which should be equal or inferior to the single-resistance selection frequency. The identification of in vitro resistance markers allows careful monitoring for their potential appearance during clinical trials. Analysis of samples during dose ranging studies for resistance selection could have an impact on dose selection, but presumably only if the changes in the IC50 value were relatively minor. Systematic monitoring of resistance selection in Phase III will consolidate the data on frequency and help to consolidate the understanding of the development of resistance in different geographic and endemicity settings. This will be important information for the regulatory filings, for national malaria control programmes, and for coordinated efforts of resistance monitoring [69]. Regulators have universally recognized the importance of a systematic approach to the characterization of new compounds in regard to their resistance generation potential. The US-FDA recommend in their ‘Guidance for Industry for Malaria drug development’ that “the ability of Plasmodium strains to develop resistance when subjected to drug pressure should be examined in appropriate in vitro and/or in vivo models; this examination should include evaluating the potential for cross-resistance to drugs in the same class or in other classes. If resistance is demonstrated, it is important to identify the mechanism of resistance. Attempts should be made to evaluate the clinical significance of any changes in phenotype (e.g., in vitro susceptibility to the drug) or genotype observed in preclinical studies by correlating such changes with clinical outcome” [70].

Characterization of resistance potential has been mentioned in the registration summaries of all anti-malarials submitted stringent regulatory authorities in the past ten years: Coartem® (artemether-lumefantrine, Novartis) to the US-FDA; Eurartesim (dihydroartemisinin-piperaquine, Sigma-Tau) at the EMA; and more recently Pyramax (pyronaridine-artesunate, Shin Poong Pharmaceuticals) which obtained marketing authorization under the EMA’s article 58 [71-73]. The MMV strategy for resistance characterization will provide this information for the regulators and ensure a complete resistance registration package.

**Conclusion**

The process presented here integrates information about the potential importance of resistance selection and spreading into the preclinical and clinical development programme for new anti-malarial drugs. At the preclinical level, the experimental framework requires a test cascade of six essential steps covered by three specific experimental procedures. The output of this workflow

---

**Figure 4 Resistance profiling and clinical development.** In vitro selection experiments typically generate resistant parasites from which resistance markers can be identified. This permits the identification of more robust combinations by assessing acquired and de novo cross-resistance studies with parasites already resistant to potential partner drugs. Resistance markers can be monitored during Phase II and III to include resistance selection as a clinical factor and to insure the appropriate resistance data package for registration. Post-marketing surveillance will also directly benefit from the a priori knowledge of resistance markers.
allows to classify the compound risk profiles as low, elevated or major (Figure 1 and 3b). This is one of the factors that will be discussed as part of the preclinical candidate selection process, a decision matrix which includes safety margin, and severity of safety signals observed, human predicted potency, speed of killing, effect on other lifecycle stages such as gametocytes and hypnozoites [74]. A major risk suggests that the compound will either face pre-existing resistance or will select new clinically significant mechanisms of resistance. This risk level should prevent further development of the compound, in the absence of a clear mitigating factor linked to major synergy in combination studies. An elevated risk is associated where there is a clear signal, and is an obvious concern. Provided that there are a small number of other elevated risks in the candidate selection matrix these compounds can be progressed, but resistance needs to be continually monitored in clinical studies, and will be a key factor in the selection of dose and combination partner. Risk mitigation is essential, making it important to understand the molecular mechanism, and to have genetic markers to survey its occurrence. A low risk classification suggests that resistance is unlikely to arise, although it is still important to continually monitor for changes in IC50 in the clinical program.

The outcome of resistance studies has several implications influencing decision making in drug development. First, the IC50 as part of the calculation for the prediction of human dose should include the range of potencies observed, and focus on the value from the most resistant parasites. This needs to be continually re-evaluated based on emerging data from primary field isolates. Second, potential cross-resistance amongst partners in drug combinations can be checked using laboratory derived resistant strains. Ideal drug combinations are these that regroup compounds driving opposed or even incompatible resistance mechanisms [75]. Third, the knowledge of in vitro identified mutations conferring resistance and susceptible genes allow monitoring during the large scale clinical trials in Phase III and post-launch, to give an early warning signal for the emergence of clinically significant effects.

The experimental strategy presented here also has limitations. It applies to compounds acting against *Plasmodium falciparum* asexual intraerythrocytic stage only. However, these represent the majority of the parasite biomass. Although the next generation of anti-malarials may include increased focus on the hepatic forms, understanding potential resistance selection at these lifecycle stages will be supported by knowledge of the resistance mechanisms in intraerythrocytic stages. Another limitation is the standardized approach itself. Resistance is a complex phenomenon that will require tailor-made studies. For instance, artemisinin resistance as currently observed does not translate into clear IC50 shift, rendering its study in cross-resistance and resistance selection experiments challenging [5]. However a standardized method does at least allow a common framework for comparing compounds and making development decisions.

The workflow presented here allows to measure the risks of resistance generation, the magnitude of the change in IC50, and the effect on transmission at an early stage in drug discovery. By determining the molecular mechanism of resistance, and identifying potential cross-resistance issues, high-risk chemical series can be de-prioritized, in a time and cost effective manner. The generation of a standard resistance profile of new drugs will supply common information to regulators and national control bodies to facilitate decision-making. This information will also allow for the focused monitoring of compounds after registration. This strategy will contribute to developing long-lasting anti-malarial drugs by identifying and monitoring robust compounds during their development.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Wrote the first draft of the manuscript and consulted with experts: XCD. Contributed to the writing of the manuscript: XCD, DU, TNCW. ICMJE criteria for authorship read and met: XCD, DU, TNCW. Agree with manuscript results and conclusions: XCD, DU, TNCW. All authors read and approved the final version of the paper.

Acknowledgements
We thank all MMV advisors and members of our External Scientific Advisory Committee and especially Arjen Dondorp, Carol Sibley, David Fidock, Dyann Wirth, Francois Nosten, Harald Noedl, Nicholas White, Pascal Ringwald, Ric Price, and Sergio Witten for insightful discussions that contributed to define the framework presented here. The authors also gratefully to Elizabeth Winzeler, Francisco-Javier Garro, Michael Makanga, Neena Valecha, Salim Abdulllah, Steve Ward, Thierry Diagana, Wallace Peters for comments and suggestions on initial thoughts about the optimal strategy to assess resistance selection. Of note, the panel of experts acknowledged here does not specifically endorse the opinions expressed in this article. The authors also acknowledge Brice Campo, Didier Leroy, Jeremy Burrows, and Thomas Spangenberg for critical comments on the manuscript.

Author details
Medicines for Malaria Venture, 20 rte de Pré Bois, Geneva CH 1215, Switzerland.

Received: 7 June 2012 Accepted: 1 August 2012
Published: 22 August 2012

References
1. Mita T, Tanabe K, Kita K: Spread and evolution of *Plasmodium falciparum* drug resistance. *Parasitol Int* 2009, 58:201–209.
2. World Health Organization: Global report on antimalarial drug efficacy and drug resistance: 2000–2010. Geneva: WHO; 2010:121.
3. Looareesuwan S, Vivian C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ: Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. *Am J Trop Med Hyg* 1996, 54:62.
4. Korinszncy M, Chen N, Kotecka B, Saul A, Reckmann K, Cheng Q: Mutations in *Plasmodium falciparum* cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. *Antimicrob Agents Chemother* 2000, 44:2100–2108.
48. Isvan ES, Dharia NV, Bopp SE, Gluzman I, Winzeler EA, Goldberg DE: Validation of isoleucine utilization targets in Plasmodium falciparum. Proc Natl Acad Sci USA 2011, 108:1627.

49. Eastman RT, Dharia NV, Winzeler EA, Fidock DA. Piperazine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother 2011, 55:3906–3916.

50. Trotta RF, Brown ML, Terrell JC, Geyer JA: Defective DNA repair as a potential mechanism for the rapid development of drug resistance in Plasmodium falciparum. Biochemistry 2004, 43:4885–4891.

51. Sanz LM, Jimenez-Diaz MB, Crespo B, De-Cozar C, Almela MJ, Angulo-Barturen I, Castaneda P, Ibanez J, Fernandez EP, Fidscher S, Herreos E, Lozano S, Martinez MS, Rueda L, Burrows, JN, Garcia-Bustos JF, Gamo FJ. Cyclopentyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen. Antimicrob Agents Chemother 2011, 55:7540–7545.

52. Cooper RA, Firdig MT, Su X-Z, Usos LMB, Mu J, Nomura T, Fujioka H, Fidock DA, Roepke PD, Wellens TE. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol Pharmacol 2002, 61:35–42.

53. Rosario VE, Hall R, Walliker D, Beale GH. Persistence of drug-resistant malaria parasites. Lancet 1978, 1:1185–1187.

54. Walliker D, Hunt P, Babiker H. Fitness of drug-resistant malaria parasites. Acta Trop 2005, 94:251–259.

55. Huljben S, Nelson WA, Wargo AR, Sim OG, Drew DR, Read AF. Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites. Evolution 2010, 64:2923–2968.

56. Hunt P, Fawcett R, Carter R, Walliker D. Estimating SNP proportions in populations of malaria parasites by sequencing: validation and applications. Mol Biochem Parasitol 2005, 143:173–182.

57. Cheesman SJ, de Roode JC, Read AF, Carter R. Real-time quantitative PCR for analysis of genetically mixed infections of malaria parasites: technique validation and applications. Mol Biochem Parasitol 2003, 131:83–91.

58. Peters JM, Chen N, Gatton M, Korsinczyk M, Fowler EV, Manzetti S, Saul A, Cheng Q. Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum. Antimicrob Agents Chemother 2002, 46:2435–2441.

59. Delves M, Plouffe D, Scheuere C, Meister S, Wüttin S, Winzeler EA, Sinden RE, Leroy D. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med 2012, 9:e1001169.

60. Peters W. The chemotherapy of rodent malaria. LVII. Drug combinations to impede the selection of drug resistance. Part I. Which model is appropriate? Ann Trop Med Parasitol 1959, 53:569–587.

61. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 1999, 33:704–711.

62. Anderson T, Nilkorna S, Ecker A, Fidock D. How can we identify parasite genes that underlie antimalarial drug resistance? Pharmacogenomics 2011, 12:69–85.

63. Dharia NV, Siddhu ARS, Cassera MR, Westenberger SJ, Bopp SE, Eastman RT, Plouffe D, Batalov S, Park DJ, Volkman SK, Wirth DF, Zhou Y, Fidock DA, Winzeler EA. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol 2009, 10:R21.

64. Su X, Firdig MT, Huang Y, Hyugh CC, Liu A, You J, Wootton JC, Wellens TE: A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science 1999, 286:1351–1353.

65. Manske M, Miotti O, Campione S, Aubum S, Almagro-Garcia J, Maslen G, O’Brien J, Djimdé A, Doumbo O, Zongo I, Oulédraogo JB, Michon P, Mueller S, Siba P, Nizila A, Bormann S, Kana SM, Marsh K, Jiang H, Su X-Z, Amaranatunga C, Fairhurst R, Sochat D, Nosten F, Imwong M, White NJ, Sanders M, Anastasi E, Alcock D, Druy E, Oyola S, Quial MA, Turner DJ, Ruano-Rubio V, Jooth D, Amengoa-Etego L, Hubbard C, Jeffreys A, Rowlands K, Sutherland C, Roper C, Mangano V, Modiano D, Tan JC, Firdig MT, Arnambua-Ngwa A, Conway DJ, Takala-Harrison S, Plowe CV, Rayner JC, Rockart KA, Clark TG, Newbold CI, Bermann M, Macinnis B, Kwiatkowski DP. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 2012, 487:375–379.

66. Volkman SK, Neafsey DE, Schaffner SF, Park DJ, Wirth DF: Harnessing genomics and genome biology to understand malaria biology. Nat Rev Genet 2012, 13:315–328.

67. Sanz LM, Crespo B, de Cozar C, Ding XC, Lierlo JL, Burrows JN, Garcia-Bustos JF, Gamo F-J, F. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS One 2012, 7:e30949.

68. Cho S, Kim S, Kim Y, Park Y. Optical imaging techniques for the study of malaria. Trends Biotechnol 2012, 30:71–79.

69. Sibley CH, Guerin PJ, Ringwald P. Monitoring antimalarial resistance: launching a cooperative effort. Trends Parasitol 2010, 26:221–224.

70. Malaria: developing drug and nonvaccine biological products for treatment and prophylaxis. http://www.fda.gov/downloads/Drugs/ Guidance/RegulatoryInformation/Guidances/UCM071951.pdf.

71. Pyramax Summary of Opinion http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/02/WC500122945.pdf.

72. Coartem Summary Review http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022628s000_SumR.pdf.

73. Euraxess Summary of Opinion http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/01/WC500108010.pdf.

74. Burrows JN, Leroy D, Lotharius J, Waterson D. Challenges in antimalarial drug discovery. Future Med Chem 2011, 3:1401–1412.

75. Cameron N. Exploiting malaria drug resistance to our advantage. Science 2011, 333:750–756.